JP2021519763A - 炎症性腸疾患を治療するための組成物及び方法 - Google Patents

炎症性腸疾患を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2021519763A
JP2021519763A JP2020552294A JP2020552294A JP2021519763A JP 2021519763 A JP2021519763 A JP 2021519763A JP 2020552294 A JP2020552294 A JP 2020552294A JP 2020552294 A JP2020552294 A JP 2020552294A JP 2021519763 A JP2021519763 A JP 2021519763A
Authority
JP
Japan
Prior art keywords
acid
subject
secondary bile
composition
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519763A5 (https=
JPWO2019191694A5 (https=
Inventor
マドヒュミタ ナンダクマール，
マドヒュミタ ナンダクマール，
エドワード ジェイ． オブライアン，
エドワード ジェイ． オブライアン，
スモン ダッタ，
スモン ダッタ，
Original Assignee
セレス セラピューティクス インコーポレイテッド
セレス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレス セラピューティクス インコーポレイテッド, セレス セラピューティクス インコーポレイテッド filed Critical セレス セラピューティクス インコーポレイテッド
Publication of JP2021519763A publication Critical patent/JP2021519763A/ja
Publication of JP2021519763A5 publication Critical patent/JP2021519763A5/ja
Publication of JPWO2019191694A5 publication Critical patent/JPWO2019191694A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020552294A 2018-03-29 2019-03-29 炎症性腸疾患を治療するための組成物及び方法 Pending JP2021519763A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650002P 2018-03-29 2018-03-29
US62/650,002 2018-03-29
PCT/US2019/025010 WO2019191694A1 (en) 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2021519763A true JP2021519763A (ja) 2021-08-12
JP2021519763A5 JP2021519763A5 (https=) 2022-04-06
JPWO2019191694A5 JPWO2019191694A5 (https=) 2022-04-06

Family

ID=66429534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552294A Pending JP2021519763A (ja) 2018-03-29 2019-03-29 炎症性腸疾患を治療するための組成物及び方法

Country Status (10)

Country Link
US (1) US20210121505A1 (https=)
EP (1) EP3773643A1 (https=)
JP (1) JP2021519763A (https=)
KR (1) KR20200138333A (https=)
CN (1) CN112118852A (https=)
AU (1) AU2019245430A1 (https=)
BR (1) BR112020019979A2 (https=)
CA (1) CA3095402A1 (https=)
MX (1) MX2020010177A (https=)
WO (1) WO2019191694A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
KR102341323B1 (ko) * 2020-07-07 2021-12-21 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
WO2025244478A1 (ko) * 2024-05-24 2025-11-27 서울대학교병원 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035804A1 (ja) * 2011-09-08 2013-03-14 カルピス株式会社 芽胞形成菌の発芽誘起方法
JP2013147469A (ja) * 2012-01-20 2013-08-01 Calpis Co Ltd 腸内酪酸産生菌増加剤
JP2016509002A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
WO2017091783A2 (en) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Designed bacterial compositions
JP2017095408A (ja) * 2015-11-25 2017-06-01 学校法人東京理科大学 消毒剤及び消毒方法
WO2017182796A1 (en) * 2016-04-19 2017-10-26 Genome Research Limited Bacteriotherapy
WO2017218680A1 (en) * 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035804A1 (ja) * 2011-09-08 2013-03-14 カルピス株式会社 芽胞形成菌の発芽誘起方法
JP2013147469A (ja) * 2012-01-20 2013-08-01 Calpis Co Ltd 腸内酪酸産生菌増加剤
JP2016509002A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
WO2017091783A2 (en) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Designed bacterial compositions
JP2017095408A (ja) * 2015-11-25 2017-06-01 学校法人東京理科大学 消毒剤及び消毒方法
WO2017182796A1 (en) * 2016-04-19 2017-10-26 Genome Research Limited Bacteriotherapy
WO2017218680A1 (en) * 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Also Published As

Publication number Publication date
US20210121505A1 (en) 2021-04-29
BR112020019979A2 (pt) 2021-03-09
CA3095402A1 (en) 2019-10-03
RU2020135433A (ru) 2022-04-29
KR20200138333A (ko) 2020-12-09
WO2019191694A1 (en) 2019-10-03
CN112118852A (zh) 2020-12-22
AU2019245430A1 (en) 2020-10-22
EP3773643A1 (en) 2021-02-17
MX2020010177A (es) 2021-01-15

Similar Documents

Publication Publication Date Title
Madhogaria et al. Correlation between human gut microbiome and diseases
US12318412B2 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
JP2021519763A (ja) 炎症性腸疾患を治療するための組成物及び方法
JP2022000040A (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
JP2023010890A (ja) 潰瘍性大腸炎を治療するための方法
JP2021152062A (ja) 過敏性腸症候群の治療のための合成組成物および方法
BR112020023933A2 (pt) composições bacterianas projetadas e usos destas
CN102711778A (zh) 利用动物双歧杆菌细菌或含有这种细菌的发酵乳制品减轻胃肠炎症的方法
CN110366420B (zh) 心理健康障碍改善用组合物
JPWO2009066681A1 (ja) 乳酸菌含有製剤
JP2022547330A (ja) 自閉症スペクトラム障害を治療するための組成物および方法
AU2008310961B2 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
Niu et al. Effect of fructooligosaccharides on the colonization of Lactobacillus rhamnosus AS 1.2466 T in the gut of mice
JP2020533008A (ja) Ｍｅｇａｍｏｎａｓ ｆｕｎｉｆｏｒｍｉｓ及びその適用
US12285447B2 (en) Methods and compositions for treating ulcerative colitis
JP6301024B2 (ja) フィーカリバクテリウム属細菌増殖剤
WO2024211569A1 (en) Compositions and methods for treating or preventing clostridium difficile infection, neutropenia, cardiovascular disease, asthma, and/or cancer
JP2025508364A (ja) 健康を改善するためのシンバイオティクス処置の方法
Akanda et al. Potential Role of Probiotics, Prebiotics, and Synbiotics in Management of Metabolic Syndrome and Chronic Metabolic Disease
WO2023099579A1 (en) Prevention or treatment of hepatic steatosis
RU2799556C2 (ru) Композиции и способы лечения воспалительных заболеваний кишечника
Finnegan et al. “Gut” to grips with the science of the microbiome–a symposium report
CN106974940A (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
WO2019155043A1 (en) Fermented formula with non-digestible oligosaccharides

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231107